Epidarex Capital

Four managing partners — A. Sinclair Dunlop, Kyparissia Sirinakis, Elizabeth Roper, and Peter Finan — collectively lead investment decisions. They are supported by two additional Partners, a Venture Partner, and a Principal. The team's backgrounds bridge academic science, pharma R&D, and early-stage venture operating experience.

Epidarex relies on a transatlantic network that interfaces directly with technology transfer offices at research universities in the UK and US mid-Atlantic. The firm focuses on institutions outside the traditional Boston–San Francisco biotech corridor. This position, combined with scientific advisory relationships, allows it to originate proprietary, often pre-formation, spin-out opportunities.

Epidarex typically acts as a seed or Series A founding investor, leading rounds and assembling syndicates. Its position as the first institutional capital into many university spin-outs allows it to shape management teams and boards, then attract follow-on funding from larger life-science specialist funds.

The firm has recorded trade sales to strategic acquirers: Harpoon Medical was acquired by Edwards Lifesciences in December 2017, Confluence Life Sciences was acquired by Aclaris Therapeutics in August 2017, and SIRAKOSS was acquired in November 2020. Apellis Pharmaceuticals reached a public listing on NASDAQ.

Epidarex operates a dual-structure with an investment team split between Bethesda, Maryland and Edinburgh, Scotland. The US office primarily covers mid-Atlantic and Southeastern university spin-outs, while the UK office covers Scottish and English university ecosystems. The two teams share a common investment committee and portfolio management framework.

Epidarex concentrates exclusively on life sciences — biotechnology, pharmaceuticals, medical devices, and health technology. It does not invest in non-healthcare sectors, digital health outside device-regulated pathways, or service-based healthcare businesses. Its negative screen excludes agricultural biotech and industrial biosciences.

Epidarex welcomes co-investors and regularly builds syndicates that include top-tier life science venture funds for later-stage follow-on rounds. The firm's model is to de-risk the science with initial capital, then bring in larger funds for Series B and beyond, often retaining board seats and pro-rata rights.